Semaglutide Alert: Telangana DCA Warns Against Unsupervised Use
Telangana DCA cautions against unsupervised semaglutide use amid rising demand.
Top Summary
- What happened: Telangana's Drug Control Administration (DCA) issued an advisory against unsupervised semaglutide use.
- Why it matters: Improper use can lead to serious health complications like pancreatitis and kidney injury.
- What changes for people: Semaglutide must only be purchased with a valid prescription from licensed medical shops.
- Who is affected: Patients using semaglutide for weight loss and Type-2 diabetes, manufacturers, and medical professionals.
Rising Semaglutide Demand Triggers Warning
The Telangana Drugs Control Administration (DCA) has issued a public advisory concerning the unsupervised use of semaglutide formulations.
This comes amid increasing demand for the drug, used for weight loss and Type-2 diabetes treatment, after the innovator product’s patent expired in March.
Health Risks of Unsupervised Use
The DCA warns that semaglutide, a prescription-only medicine, must be used under the strict supervision of a registered medical practitioner.
Improper or unsupervised use can lead to serious health complications.
These include acute pancreatitis, acute kidney injury, severe gastrointestinal reactions, and gall bladder disease.
Doctor's Role and Prescription Requirements
Qualified doctors must assess a patient’s medical history, existing conditions, and risk factors before prescribing semaglutide.
They also determine the appropriate dosage and duration of treatment.
Semaglutide formulations must be purchased only from licensed medical shops and strictly against a valid prescription.
Crackdown on Illegal Sales and Promotion
The DCA warns against procuring the drug through unregulated online platforms or unauthorized sellers.
Such products could be spurious, substandard, or unsafe.
The public is urged to report any instances of illegal sale, promotion, or misuse of semaglutide formulations.
Manufacturers were directed not to engage in surrogate advertising or indirect promotion that could mislead consumers or encourage off-label use.
Manufacturer Guidelines
Manufacturers are prohibited from engaging in surrogate advertising or indirect promotion.
This is to prevent misleading consumers or encouraging off-label use.
What to Watch Next
The Telangana DCA will likely continue monitoring semaglutide sales and usage. Further advisories or actions may be taken based on compliance and reported incidents to ensure public safety.